Hospitals | May 23, 2026
Fortis Healthcare FY26 revenue crosses Rs. 9,100 crore
Q4 FY26 PAT jumps 44% to Rs. 271 crore, supported by acquisitions, specialty expansion, and diagnostics momentum
Q4 FY26 PAT jumps 44% to Rs. 271 crore, supported by acquisitions, specialty expansion, and diagnostics momentum
The trial will assess Precem-TcT, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments
SFDA nod marks company’s strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region
Organizations that embrace it thoughtfully today will help shape a healthier tomorrow, for India and beyond
Q4FY26 revenue rises 13.6% to Rs. 14,560 crore; quarterly net profit jumps 26.2% to Rs. 2,714 crore driven by India business and Innovative Medicines growth
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
US federal jury finds Japanese drugmaker liable for anticompetitive agreement delaying generic version of constipation drug Amitiza
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
Combined platform with 55+ centres aims to expand integrated maternity, fertility, neonatal and paediatric care across India
SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
Subscribe To Our Newsletter & Stay Updated
